Celldex Therapeutics
CLDX
51 hedge funds and large institutions have $10.4M invested in Celldex Therapeutics in 2019 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 13 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
43% more call options, than puts
Call options by funds: $201K | Put options by funds: $141K
4.05% more ownership
Funds ownership: 23.07% → 27.12% (+4.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 53 → 51 (-2)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
30% less capital invested
Capital invested by funds: $14.9M → $10.4M (-$4.47M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
+$1.55M |
| 2 |
Renaissance Technologies
New York
|
+$1.25M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$409K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$276K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$241K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$644K |
| 2 |
D.E. Shaw & Co
New York
|
-$292K |
| 3 |
VF
Virtu Financial
New York
|
-$127K |
| 4 |
Bank of New York Mellon
New York
|
-$126K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$81.1K |
CLDX Hedge Fund Activity: Q2 2019 in Review
51 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q2 2019, worth a combined $10.4M — down 30% from $14.9M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CLDX and 11 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 14 added.
The largest buyer was Cresset Asset Management, opening a new position worth an estimated $1.55M. The largest seller was Vanguard Group, cutting an estimated $644K.
- 51 institutional investors held Celldex Therapeutics (CLDX) as of Q2 2019, down from 53 in Q1 2019.
- Funds reported $10.4M of Celldex Therapeutics stock for Q2 2019, down 30% quarter-over-quarter.
- 11 funds opened new Celldex Therapeutics positions in Q2 2019 and 13 closed out, a net change of -2 holders.
- The largest Celldex Therapeutics buyer in Q2 2019 was Cresset Asset Management, an estimated $1.55M added.
- The largest Celldex Therapeutics seller in Q2 2019 was Vanguard Group, an estimated $644K sold.
Based on aggregated 13F filings for Q2 2019.